Reply to "The Effects of Newer Antidepressants on Low-Density Lipoprotein Cholesterol Levels"

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

We appreciate Le Mellédo and colleagues’ interest in our work. Their point is well taken: our 4-week study may not have detected changes in levels of low-density lipoprotein cholesterol (LDL-C) and other lipids that could have reached statistical significance only after 8 or more weeks of mirtazapine exposure. However, we deliberately chose to study healthy control subjects in order to avoid potential confounding effects of a psychiatric disease state per se in our investigation of the effects of mirtazapine. For practical and ethical considerations, we limited the exposure of these healthy subjects to 1 month.

J Clin Psychiatry 2004;65(7):1018-1018